<DOC>
	<DOC>NCT02954081</DOC>
	<brief_summary>Patient treatment preference and treatment satisfaction of physicians and patients comparing fumaric acid ester therapy with subsequent apremilast treatment</brief_summary>
	<brief_title>APremilast After FumaRic Acid Ester Treatment</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Adult patients ≥18 years Moderate to severe plaquetype psoriasis according to SmPC Phase I: Patients will be included once they are started on systemic fumaric acid esters (e.g. Fumaderm initial®) for the treatment of moderatetosevere psoriasis vulgaris. Patients initiated on fumaric acid esters will be followed for a maximum of 24 weeks during phase I. Patients continued on fumaric acid esters beyond 24 weeks or switched to a therapy other than apremilast during or at the end of the 24week phase I period will no longer be followed. Phase II: Patients switched to apremilast during or at the end of the 24week phase I period will be included in phase II and followed for additional 32 weeks. Written informed consent Prior treatment with biologics According to SmPC Participation in another clinical trial (parallel inclusion in the National psoriasis registry PsoBest is allowed)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>